News & Events about Intellia Therapeutics Inc.
Intellia Therapeutics, Inc.(NASDAQ: NTLA) shares are up Thursday as its Q1 results surpassed estimates. The company looks forward to sharing new interim data from NTLA-2001 and NTLA-2002 first-in-human studies in the coming months.
read more...
Fool.com Headlines
1month ago
These stocks have some promising growth opportunities, but they also come with a fair amount of risk.Are you looking for some growth stocks than can double in value? Two stocks that analysts appear to be bullish on right now are Intellia Therapeutics (NASDAQ: NTLA) and Rivian Automotive(NASDAQ: RIVN...
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA Get Rating) have received a consensus recommendation of Moderate Buy from the nineteen research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell ...
Globe Newswire
2 months ago
NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAECAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on ...
Ticker Report
3 months ago
Intellia Therapeutics (NASDAQ:NTLA Get Rating) had its price objective trimmed by Chardan Capital from $129.00 to $111.00 in a research report sent to investors on Friday, The Fly reports. NTLA has been the topic of several other research reports. Oppenheimer decreased their target price on ...